IN VITRO PERMEABILITY ASSAYS AS A TOOL IN ADME
Intestinal epithelium permeability is a critical characteristic that determines the rate and extent of human absorption and ultimately affects the bioavailability of a drug candidate. Therefore, permeability assays are very important for pharmaceutical development and oral bioavailability. The Caco-2 monolayer permeability model is actually accepted and regulated by FDA and EMA as a tool in Drug Discovery processes.
Caco-2 assay is the method of general choice because it expresses cytochrome P450 enzymes, transporters, microvilli in an enterocyte-like fashion, exhibiting similar characteristics to the human small intestine. However, it is resource-intensive due to requirements of cell culture, stock maintenance and experimental set up. It requires a precise length of differentiation (21 days) which also affects to results output.
By using ReadyCell Ready-to-Use Caco-2 based kits, permeability assays could be not only more flexible and cost effective, but also more reproducible between and among batches and also easily comparable between different locations and laboratories.
A CELL-BASED AND READY-TO-USE CONCEPT
FOR IN VITRO INTESTINAL ABSORPTION EVALUATION
CacoReady™ is an innovative cell-based and ready-to-use kit.
The kit consists of 24 and 96 insert-integrated permeable support seeded with differentiated and polarized Caco-2 barriers on polycarbonate microporous filters.
CacoReady™ Allows in vitro intestinal absorption evaluation of drug targets. CacoReady™ is flexible since plates can be used up to 5 days after ideal cell barrier differentiation at day 21. CacoReady™ is a time and cost-saving tool for early stage drug discovery and development.
A MUCUS SECRETING READY-TO-USE CONCEPT FOR IN VITRO INTESTINAL ABSORPTION EVALUATION
CacoGoblet, a mucus-secreting ready-to-use kit. The kit consists of 24 permeable supports seeded with differentiated polarized Caco-2 and human goblet cells.
CacoGoblet, allows in vitro intestinal absorption evaluation of drug targets in a barrier physiologically closer to the intestinal epithlium.
CacoGoblet is flexible, since plates can be used up to 5 days after ideal cell barrier differentation at day 21, being a time and cost-saving tool for early stage drug discovery and development.